LipidDB ID

LipidDB-9606-00837

Entry Name

UniProt Accession

P07550; B0LPE4; B2R7X2; O14823; O14824; O14825; O14826; Q4JG18; Q53GA6; Q6GMT4; Q6P4D8; Q8NEQ9; Q96EC3; Q9UCZ0; Q9UCZ1; Q9UCZ2; Q9UCZ3; Q9UH95; Q9UHA1; Q9UMZ5;

Theoretical PI

6.59

Molecular Weight

46458.67

Genbank Protein ID

CAA28511.1; CAA68289.1; AAA88015.1; AAA88017.1; AAB82148.1; AAB82149.1; AAB82150.1; AAB82151.1; AAD48036.1; AAF17569.1; AAF20199.1; AAN01267.1; BAG35969.1; BAD96745.1; AAY88739.1; ABY87523.1; EAW61798.1; AAH12481.3; AAH63486.2; AAH73856.1;

Genbank Nucleotide ID

X04827; Y00106; M15169; J02960; AF022953; AF022954; AF022955; AF022956; AF169225; AF202305; AF203386; AY136741; AK313151; AK223025; DQ094845; EU332834; CH471062; BC012481; BC063486; BC073856;

Protein Name

Beta-2 adrenergic receptor

Protein Synonyms/Alias

Beta-2 adrenoreceptor; Beta-2 adrenoceptor;

Gene Name

ADRB2

Gene Synonyms/Alias

ADRB2R; B2AR;

Created Date

01-APR-1988

Organism

Homo sapiens (Human)

NCBI Taxa ID

9606

Reference

[1] O'Dowd BF, Hnatowich M, Caron MG, Lefkowitz RJ, Bouvier M. Palmitoylation ofthe human beta 2-adrenergic receptor. Mutation of Cys341 in the carboxyl tailleads to an uncoupled nonpalmitoylated form of the receptor. J Biol Chem. 1989May 5;264(13):7564-9.[PMID:2540197]
[2] Trester-Zedlitz M, Burlingame A, Kobilka B, von Zastrow M. Mass spectrometric analysis of agonist effects on posttranslational modifications of the beta-2adrenoceptor in mammalian cells. Biochemistry. 2005 Apr 26;44(16):6133-43. PubMedPMID: 15835901.[PMID:15835901]

Functional Description

Beta-adrenergic receptors mediate the catecholamine- induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.

Sequence Annotation

Topological domain: 1 34 Extracellular.
Transmembrane: 35 58 Helical; Name=1.
Topological domain: 59 71 Cytoplasmic.
Transmembrane: 72 95 Helical; Name=2.
Topological domain: 96 106 Extracellular.
Transmembrane: 107 129 Helical; Name=3.
Topological domain: 130 150 Cytoplasmic.
Transmembrane: 151 174 Helical; Name=4.
Topological domain: 175 196 Extracellular.
Transmembrane: 197 220 Helical; Name=5.
Topological domain: 221 274 Cytoplasmic.
Transmembrane: 275 298 Helical; Name=6.
Topological domain: 299 305 Extracellular.
Transmembrane: 306 329 Helical; Name=7.
Topological domain: 330 413 Cytoplasmic.
Region: 193 207 Agonist and antagonist binding.
Region: 286 293 Agonist and antagonist binding.
Region: 312 316 Agonist and antagonist binding.
Motif: 410 413 PDZ-binding.
Binding site: 113 113 Agonist or antagonist.
Binding site: 118 118 Agonist or antagonist.
Modified residue: 141 141 Phosphotyrosine.
Modified residue: 246 246 Phosphoserine.
Modified residue: 261 261 Phosphoserine; by PKA.
Modified residue: 262 262 Phosphoserine; by PKA.
Modified residue: 345 345 Phosphoserine; by PKA.
Modified residue: 346 346 Phosphoserine; by PKA.
Modified residue: 355 355 Phosphoserine; by BARK.
Modified residue: 356 356 Phosphoserine; by BARK.
Modified residue: 382 382 4-hydroxyproline.
Modified residue: 395 395 4-hydroxyproline.

Protein Length

413 AA.

Protein Sequence
(Canonical)

FASTA
(Canonical)

Gene Ontology

GO:0016324; C:apical plasma membrane; IEA:Ensembl
GO:0005768; C:endosome; TAS:ProtInc
GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL
GO:0005764; C:lysosome; TAS:ProtInc
GO:0005634; C:nucleus; IEA:Ensembl
GO:0005886; C:plasma membrane; IDA:MGI
GO:0043235; C:receptor complex; IDA:HGNC
GO:0004941; F:beta2-adrenergic receptor activity; IDA:HGNC
GO:0051380; F:norepinephrine binding; IDA:HGNC
GO:0015459; F:potassium channel regulator activity; IDA:BHF-UCL
GO:0042803; F:protein homodimerization activity; IDA:HGNC
GO:0007190; P:activation of adenylate cyclase activity; IDA:HGNC
GO:0007171; P:activation of transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc
GO:0007189; P:adenylate cyclase-activating G-protein coupled receptor signaling pathway; IEA:Ensembl
GO:0007188; P:adenylate cyclase-modulating G-protein coupled receptor signaling pathway; TAS:ProtInc
GO:0071875; P:adrenergic receptor signaling pathway; IDA:GOC
GO:0045453; P:bone resorption; IEA:Ensembl
GO:0050873; P:brown fat cell differentiation; IEA:Ensembl
GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc
GO:0002032; P:desensitization of G-protein coupled receptor protein signaling pathway by arrestin; IDA:HGNC
GO:0002024; P:diet induced thermogenesis; IEA:Ensembl
GO:0008333; P:endosome to lysosome transport; TAS:ProtInc
GO:0031649; P:heat generation; IEA:Ensembl
GO:0040015; P:negative regulation of multicellular organism growth; IEA:Ensembl
GO:0045986; P:negative regulation of smooth muscle contraction; IEA:Ensembl
GO:0030501; P:positive regulation of bone mineralization; IEA:Ensembl
GO:0043410; P:positive regulation of MAPK cascade; IDA:HGNC
GO:0031398; P:positive regulation of protein ubiquitination; IMP:BHF-UCL
GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl
GO:0006898; P:receptor-mediated endocytosis; IDA:HGNC
GO:0002028; P:regulation of sodium ion transport; IEA:Ensembl
GO:0042312; P:regulation of vasodilation; IEA:InterPro
GO:0009409; P:response to cold; IEA:Ensembl
GO:0002025; P:vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure; IEA:Ensembl

Interpro

InterPro; IPR002233; ADR_fam
InterPro; IPR000332; ADRB2_rcpt
InterPro; IPR000276; GPCR_Rhodpsn
InterPro; IPR017452; GPCR_Rhodpsn_7TM

Pfam

Pfam; PF00001; 7tm_1;

SMART

PROSITE

PROSITE; PS00237; G_PROTEIN_RECEP_F1_1;
PROSITE; PS50262; G_PROTEIN_RECEP_F1_2;

PRINTS

PRINTS; PR01103; ADRENERGICR;
PRINTS; PR00562; ADRENRGCB2AR;
PRINTS; PR00237; GPCRRHODOPSN;